BioTime, Inc. s trend and data analysis indicates that the stock price has dropped -5.53% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -7.95% . Looking at the past 52 week period, the stock price is up at 42.46% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of BioTime, Inc. has a positive value of 7.19 compared to overall market.BioTime, Inc. is having a Relative Strength Index of 62.88 which indicates the stock is not yet over sold or over bought based on the technical indicators.
BioTime, Inc. (NYSEMKT:BTX) has climbed 14.7% in the past week and advanced 20.88% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 14.42% and the outperformance has advanced to 19.5% for the last 4 weeks period.
For this week, the average consensus of the stock is rated as a Strong Buy. BioTime, Inc. (NYSEMKT:BTX) : On Friday heightened volatility was witnessed in BioTime, Inc. (NYSEMKT:BTX) which led to swings in the share price. The stock opened for trading at $3.07 and hit $3.62 on the upside , eventually ending the session at $3.59, with a gain of 15.81% or 0.49 points. The heightened volatility saw the trading volume jump to 1,506,410 shares. The 52-week high of the share price is $4.005 and the company has a market cap of $398 million. The 52-week low of the share price is at $2.255 .
Company has reported several Insider transactions to the SEC, on Jan 22, 2016, Alfred D Kingsley (director officer 10% owner ) sold 300,000 shares at 2.35 per share price.On Nov 11, 2015, Angus C. Russell (director) purchased 50,000 shares at 3.83 per share price.On Nov 10, 2015, Stephen C Farrell (director) purchased 50,000 shares at 3.83 per share price.
BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTimes research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.